Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity
Sara Falck-Jones, … , Anna Färnert, Anna Smed-Sörensen
Sara Falck-Jones, … , Anna Färnert, Anna Smed-Sörensen
Published January 25, 2021
Citation Information: J Clin Invest. 2021;131(6):e144734. https://doi.org/10.1172/JCI144734.
View: Text | PDF
Research Article Immunology

Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity

  • Text
  • PDF
Abstract

The immunopathology of coronavirus disease 2019 (COVID-19) remains enigmatic, causing immunodysregulation and T cell lymphopenia. Monocytic myeloid-derived suppressor cells (M-MDSCs) are T cell suppressors that expand in inflammatory conditions, but their role in acute respiratory infections remains unclear. We studied the blood and airways of patients with COVID-19 across disease severities at multiple time points. M-MDSC frequencies were elevated in blood but not in nasopharyngeal or endotracheal aspirates of patients with COVID-19 compared with healthy controls. M-MDSCs isolated from patients with COVID-19 suppressed T cell proliferation and IFN-γ production partly via an arginase 1–dependent (Arg-1–dependent) mechanism. Furthermore, patients showed increased Arg-1 and IL-6 plasma levels. Patients with COVID-19 had fewer T cells and downregulated expression of the CD3ζ chain. Ordinal regression showed that early M-MDSC frequency predicted subsequent disease severity. In conclusion, M-MDSCs expanded in the blood of patients with COVID-19, suppressed T cells, and were strongly associated with disease severity, indicating a role for M-MDSCs in the dysregulated COVID-19 immune response.

Authors

Sara Falck-Jones, Sindhu Vangeti, Meng Yu, Ryan Falck-Jones, Alberto Cagigi, Isabella Badolati, Björn Österberg, Maximilian Julius Lautenbach, Eric Åhlberg, Ang Lin, Rico Lepzien, Inga Szurgot, Klara Lenart, Fredrika Hellgren, Holden Maecker, Jörgen Sälde, Jan Albert, Niclas Johansson, Max Bell, Karin Loré, Anna Färnert, Anna Smed-Sörensen

×

Figure 5

T cells in patients with COVID-19.

Options: View larger image (or click on image) Download as PowerPoint
T cells in patients with COVID-19.
Total lowest (A) CD4+ and (B) CD8+ T ...
Total lowest (A) CD4+ and (B) CD8+ T cell count in blood was calculated for HCs (n = 9) and for patients with COVID-19 across disease severities: mild, n = 8; moderate, n = 29; severe, n = 32; and fatal, n = 7. (C) Spearman’s correlation between the total CD3+ T cell count in blood and the peak M-MDSC frequency. (D) Gating strategy for CD3ζ chain analysis. Live, single CD3+ cells were identified and separated into CD4+ or CD8+ T cell groups. The median fluorescence intensity (MFI) was calculated for both cell populations. The blue histogram represents the fluorescence-minus-one (FMO) control, and the red histogram represents CD3ζ (phycoerythrin-labeled [PE-labeled]). FSC-A, forward scatter area; SSC-A, side scatter area. (E and F) Thawed PBMCs from 11 patients with COVID-19, 4 patients with influenza, and 12 matched HCs were intracellularly stained for CD3ζ chain expression. The MFI was calculated for (E) CD4+ and (F) CD8+ T cells. *P ≤ 0.05, **P < 0.01, and ***P < 0.001. Comparison of medians between the groups was performed using the Kruskal-Wallis test with Dunn’s post hoc multiple-comparison test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts